Zyrubin 50 Injection

Description of Zyrubin 50 (Epirubicin 50mg) injection

Zyrubin 50 injection is composed of Epirubicin, an antineoplastic agent which is a member of the anthracycline antibiotic group. It is mostly prescribed in the treatment of the solid tumours, especially the breast cancer and other malignancies. Epirubicin has a therapeutic effect which is mediated by perturbation of DNA replication and transcription in malignancies that proliferate rapidly. In a physiological context, genomic integrity is fundamental in the survival and multiplication of cells, and derailing these mechanisms, Epirubicin inhibits in an effective way the proliferation of tumour cells. Epirubicin has been considered to have a relatively low tendency towards cardiotoxicity and maintain a high anticancer activity when compared with other anthracycline drugs, which is why it is used either as monotherapy or in combination with other chemotherapeutic drugs.

Indications of Zyrubin 50 (Epirubicin 50mg) injection

Epirubicin is used to treat breast cancer, ovarian cancer, gastric cancer, soft -tissue sarcoma, and bladder cancer. It is often used in combination chemotherapy with its choice being based on the clinical condition and the level of stage of the disease of the patient.

Mechanism of action of Zyrubin 50 (Epirubicin 50 mg) injection

It is the therapeutic effect of Epirubicin through several mechanisms. The drug intercalates into DNA strands thus disrupting the chromatin structure and functions. It also inhibits the topoisomerase II which is very important in the DNA replication and in repairing and causes the DNA strand breaks to be formed. Also, Epirubicin produces reactive oxygen species causing oxidative damage to cellular constituents. The net effect of these cumulative effects is programmed cells death in malignant cells and inhibition of tumour progression.

How to consume Zyrubin 50 (Epirubicin 50 mg) injection

Epirubicin is given by infusion intravenously and under strict care of qualified health care experts. The dosage is determined according to the surface area of the body, the pathology of the disease of the case, and the therapeutic response. The programme usually includes a series of repetitions that last few weeks. Intravesical administration is used in the case of bladder cancer in selected cases. Precaution should also be taken to avoid extravasation that can cause severe local tissue damage during administration.

Side Effects of Zyrubin 50 (Epirubicin 50 mg) injection

1. Common side effects

• Nausea
• Vomiting
• Alopecia
• Fatigue
• Mucositis

2. Serious side effects

• Bone marrow suppression
• Neutropenia
• Cardiotoxicity
• Anemia
• Thrombocytopenia

3. Rare side effects

• Secondary leukemia
• Hypersensitivity reactions
• Hepatotoxicity
• Tissue necrosis

Safety Advice for Zyrubin 50 (Epirubicin 50 mg) injection

The patients under Epirubicin treatment must receive regular observation of haematological indexes, hepatic functional parameters, and cardiac examination.

Breastfeeding: Epirubicin is contraindicated when used in lactation since the drug could accumulate in the breast milk and have an adverse effect on the baby.

Pregnancy: The drug should not be used during pregnancy because it may cause severe effects to the developing foetus.

Alcohol: The alcohol consumption must be minimised due to the possibility of raising the hepatic toxicity and worsening adverse effects.

Liver: Patients with hepatic impairment must have dose alteration and closely monitored since the drug is broken down in the liver.

Lungs: Patients are expected to report any difficulty in breathing especially when administered together with other chemotherapeutic drugs.

Kidney: Rose medical care to keep an eye on renal functioning in case of having pre-existing renal disease.

Driving: Fatigue and weakness may arise and therefore, cannot drive in the event that such symptoms are experienced.

Interaction of Zyrubin 50 (Epirubicin 50 mg) injection

• Drug–Drug Interaction

Cyclophosphamide x Epirubicin. 

Such combination can increase myelosuppression and increase the total toxicity, so close monitoring is required.

Trastuzumab  x Epirubicin 

Corcomitant treatment significantly contributes to the risk of cardiotoxicity, such as heart failure.

Paclitaxel x Epirubicin 

Paclitaxel can increase epirubicin systemic levels, and hence increase toxicity.

Cimetidine x Epirubicin 

Cimetidine has the potential of inhibiting drug metabolism leading to higher plasma concentration of epirubicin.

Warfarin x Epirubicin 

Such combination can increase haemorrhagic risks because of thrombocytopenia and changed coagulation cascades.

• Drug–Food Interaction

Epirubicin is used orally (intravenously); thus, the effect of food on its absorption is not observed, however, a balanced diet can also help to recover and prevent fatigue.

• Drug–Disease Interaction of Zyrubin 50 (Epirubicin 50 mg) injection

Cardiac disease 

Compromised cardiac disease patients are at more risk since over time with the use of epirubicin, myocardial integrity may be gradually damaged, and cardiotoxicity can occur.

Bone marrow suppression 

The medication inhibits haematopoiesis; therefore, patients with already existing bone marrow diseases can obtain severe complications.

Liver disease 

The problem of impaired hepatic functioning may lead to accumulation of epirubicin, which increases the likelihood of toxicity.

Infections  

Epi-immunosuppression in relation to epirubicin can make one more vulnerable to contracting infections, and comorbid infections can advance.

Contraindication of Zyrubin 50 (Epirubicin 50 mg) injection.

Epirubicin should not be used in individuals with severe cardiovascular disease, severe myelosuppression, anthracycline hypersensitivity and pregnancy.

Dosage of Zyrubin 50 (Epirubicin 50 mg) injection

Dosage is calculated based on body surface area and it is used in repeated cycles under the guidance of a medical professional; accumulation of dose is also observed with the aim of the chance of cardiotoxicity being reduced.

Storage of Zyrubin 50 (Epirubicin 50 mg) injection

Keep the drug in the recommended conditions and avoid exposure to heat and light and ensure they do not reach the hands of children.

Missed Dose of Zyrubin 50 (Epirubicin 50 mg) injection

Since the medication is taken in a hospital, the patient will not be likely to miss a dosage; the treating physician will take care of any lateness.

Other General Information of Zyrubin 50 (Epirubicin 50 mg) injection

The patients are supposed to be well hydrated, fed, and kept in good oral condition. Haematological indices, liver functioning, and heart condition should be checked regularly. Chest pains, fever, or abnormal haemorrhage are some of the symptoms that must be reported as soon as possible.

FAQs of Zyrubin 50 (Epirubicin 50 mg) injection

1. What is the use of Epirubicin in the treatment of cancer?

Epirubicin achieves its therapeutic action by causing malignant cells to suffer DNA damage, thus halting the cell proliferation as well as causing them to undergo apoptosis.

2. Is Epirubicin capable of heart effects?

Yes, especially long-term exposure to epirubicin can also result in cardiotoxicity, and this should be monitored.

3. Is hair loss permanent?

No, the epirubicin-related alopecia is temporary and it generally subsides when the therapy is over.

4. What is the rationale of conducting regular blood tests?

They help in the early identification of myelosuppression and other negative influences.

5. Epirubicin Can be used together with other drugs?

Yes, epirubicin may be used as a part of regimens so that it increases therapeutic efficacy.

Fact Box of Zyrubin 50 (Epirubicin 50 mg) injection

Field	Details
Generic/Molecule Name	Epirubicin
Therapeutic Class	Anti-neoplastic agent
Pharmacological Class	Anthracycline antibiotic
Dosage form	Injection
Habit forming	No
Indication	Breast cancer, ovarian cancer, gastric cancer

 

References

• FDA Prescribing Information – Epirubicin Hydrochloride
  https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050795s036lbl.pdf
• National Cancer Institute (NCI) – Epirubicin
  https://www.cancer.gov/about-cancer/treatment/drugs/epirubicin
• DrugBank – Epirubicin Profile
  https://go.drugbank.com/drugs/DB00445
• European Medicines Agency (EMA) – Epirubicin Product Information
  https://www.ema.europa.eu/en/documents/overview/epirubicin